Advanced Hematology Diagnostics: Exceptional Accuracy and Testing Efficiency

Precipio creates proprietary hematology diagnostic products that help laboratories achieve faster and more efficient throughput, improve their economics, and most importantly, deliver superior diagnostic accuracy to patients and physicians.

BloodhoundTM Molecular Kits

Detection of BCR::ABL1 isoforms, ABL1 kinase domain mutations, and MPN-related mutations

HemeScreen® Molecular Kits

Detection of MPN, CLL, AML, MDS-related mutations

IV-CellTM Culture Media

Multi-cell lineage culturing media. Simplified workflow & unparalleled clinical accuracy

Clinical Services

Hematopathology diagnostic services at the highest level of accuracy, quality, and service

Clinical Hematology Lab Services

We deliver superior hematology diagnostic accuracy to patients and physicians

We do this by capturing insights from our cancer diagnostics clinical laboratory, selecting our best technologies to commercialize into products, and selling them through a network of global distribution partners.

Clinical Hematopathology Diagnostics at the Highest Level of Accuracy, Quality, and Service

1 in 4 blood cancer patients is misclassified. We get it right from the start through cutting-edge technology and unparalleled expertise.

Learn More

We develop proprietary technologies to meet the diagnostic needs of personalized medicine with faster turn around times.

Learn More

A second opinion from a world-class specialized expert provides patients & physicians peace of mind that their treatment plan is on the right track.

Learn More

Our Culture

Precipio’s culture is one of care. The company exists to battle a problem that affects hundreds of thousands of patients, and their families, each year. Every patient that is impacted by the work we do, is treated with the same care we would treat our own family.

Hands together

Innovative Technology

View Hematology Lab Products

BloodhoundTM BCR-ABL1

HemeScreen® AML

BloodhoundTM ABL1 Resistance

HemeScreen® Cytopenia

BloodhoundTM MPN

HemeScreen® CLL

HemeScreen® MPN

IV-Cell™ Cytogenetics Culture Medium

The Latest at Precipio

News & Events

Precipio, Inc. Announces Adjournment of Annual Meeting of Stockholders

New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time. NEW HAVEN, CT, [...]

Read More
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

The cost of a rescheduled shareholder meeting could reach $100,000 NEW HAVEN, CT, (June 12th, [...]

Read More
Precipio Provides Status Update on Current Business Matters

NEW HAVEN, CT, (June 12th, 2024) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) provides [...]

Read More

Stay up to date on the latest news and information.
Sign up for our newsletter